ASH 2022: Zanubrutinib in Patients With Relapsed or Refractory CLL/SLL
Posted: 02/01/2023 | By: Chase Doyle

In the randomized phase III ALPINE study, zanubrutinib was compared head-to-head with ibrutinib as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Brown et al presented results from a progression-free survival analysis of the trial at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract LBA-6).

Question 1 of 5

How did the progression-free survival rates compare between patients taking zanubrutinib and ibrutinib in the ALPINE trial?

Choose 1